Sealed AIR
SEALED AIR CORP/DE
Key figures
Period Jan 2025 to Dec 2025ConsolidatedU.S. GAAP
RevenueDisclosed
US$5.4B
Operating marginCalculated
13.5%
Net assets to total assetsCalculated
17.6%
Company profile
Tables scroll sideways
Disclosed data
Profitability
★★★★☆position among all companies
13.5%
Growth (revenue, 4-year average)
★☆☆☆☆position among all companies
-0.8%
Capital efficiency
★★★★★position among all companies
40.8%
Revenue and profit
Performance, financial position and capital allocation
Sealed AIR
Recent performance trends
Sealed AIR
Cash flow trends
Consolidated indicators (9 items)
| Item | 4 years ago | 3 years ago | 2 years ago | Last year | This year |
|---|---|---|---|---|---|
| Net sales | US$5.5 billion | US$5.6 billion | US$5.5 billion | US$5.4 billion | US$5.4 billion |
| Operating income | US$0.9 billion | US$0.9 billion | US$0.8 billion | US$0.7 billion | US$0.7 billion |
| Net income | US$0.5 billion | US$0.5 billion | US$0.3 billion | US$0.3 billion | US$0.5 billion |
| Total assets | US$6.2 billion | US$6.2 billion | US$7.2 billion | US$7.0 billion | US$7.0 billion |
| Shareholders' equity | US$0.2 billion | US$0.3 billion | US$0.5 billion | US$0.6 billion | US$1.2 billion |
| Net cash provided by (used in) operating activities | US$0.7 billion | US$0.6 billion | US$0.5 billion | US$0.7 billion | US$0.6 billion |
| Net cash provided by (used in) investing activities | US$-0.1 billion | US$-0.2 billion | US$-1.4 billion | US$-0.2 billion | US$-0.1 billion |
| Net cash provided by (used in) financing activities | US$-0.6 billion | US$-0.4 billion | US$0.8 billion | US$-0.4 billion | US$-0.6 billion |
| Cash and cash equivalents | US$0.6 billion | US$0.5 billion | US$0.3 billion | US$0.4 billion | US$0.3 billion |
Revenue scale in the same industry
Sealed AIR
Chemicals and pharmaceuticals: 56 companies · revenue · largest first・each company’s latest fiscal year・Consolidated・Disclosed
- 1 Johnson & JohnsonFY Dec 2025 US$94.2B
- 2 Procter & GambleFY Jun 2026 US$87.0B
- 3 ELI Lilly ANDFY Dec 2025 US$65.2B
- … 34 companies
- 38 CotyFY Jun 2026 US$5.8B
- 39 HuntsmanFY Dec 2025 US$5.7B
- 40 Sealed AIRThis companyFY Dec 2025 US$5.4B
- 41 Beone MedicinesFY Dec 2025 US$5.3B
- 42 AlbemarleFY Dec 2025 US$5.1B
- … 14 companies
Sources and methodology
Basic indicators
| Item | Value | Consolidated / Non-consolidated | Source |
|---|---|---|---|
| Purchase of property, plant and equipment | US$0.2 billion | Consolidated | Disclosed |
| Cash and cash equivalents | US$0.3 billion | Consolidated | Disclosed |
| Net cash provided by (used in) financing activities | US$-0.6 billion | Consolidated | Disclosed |
| Net cash provided by (used in) investing activities | US$-0.1 billion | Consolidated | Disclosed |
| Net cash provided by (used in) operating activities | US$0.6 billion | Consolidated | Disclosed |
| Depreciation and amortization | US$0.2 billion | Consolidated | Disclosed |
| Dividends paid | US$0.1 billion | Consolidated | Disclosed |
| Net assets | US$1.2 billion | Consolidated | Disclosed |
| Net sales | US$5.4 billion | Consolidated | Disclosed |
| Operating income | US$0.7 billion | Consolidated | Disclosed |
| Net income | US$0.5 billion | Consolidated | Disclosed |
| Total assets | US$7.0 billion | Consolidated | Disclosed |
| Purchase of treasury stock | US$0 | Consolidated | Disclosed |
| Operating margin | 13.5% | Consolidated | Calculated |
| Net assets to total assets | 17.6% | Consolidated | Calculated |
| Net margin | 9.4% | Consolidated | Calculated |
| Return on equity | 40.8% | Consolidated | Calculated |